GlassScriptPhysician profile
Seth T Howell
NPI 1225532369
$53,406.90
in general payments reported to CMS, 2019-2025
16 companies · $51K in 2025
The $51K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $504 · 2024: $1,400 · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $4,570 · Travel and Lodging: $2,988 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,728.00 |
| Food and Beverage | $4,570.15 |
| Travel and Lodging | $2,988.37 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $50,863.04 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $571.38 | 2024-2025 | |
| Amgen INC. | $451.05 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $375.62 | 2023-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $232.45 | 2023-2025 | Ilumya |
| Lilly USA, LLC | $208.39 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $183.87 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $166.28 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.05 | 2024-2025 | Spevigo |
| Incyte Corporation | $70.29 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $51.73 | 2024-2025 | Adbry, Spevigo |
| Dermavant Sciences, INC. | $31.34 | 2023 | Vtama |
| Janssen Biotech, INC. | $30.64 | 2024-2025 | Tremfya |
| Pfizer INC. | $18.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.09 | 2025 | Sotyktu |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $17.23 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.